For example, the potential efficacy of anti-angiogenic therapy for pancreatic cancer [9,10], including controlled clinical trials on anti-VEGF (vascular endothelial growth factor) monoclonal antibody bevacizumab and anti-EGFR (epidermal growth factor receptor) monoclonal antibody cetuximab, failed to demonstrate a survival benefit of these anti-angiogenic therapies for patients [11,12]. The gene discussed is VEGFA; the disease is pancreatic neoplasm.